Comparative study of low-dose ketamine infusion and repetitive transcranial magnetic stimulation in treatment-resistant depression: A posthoc pooled analysis of two randomized, double-blind, placebo-controlled studies

被引:5
|
作者
Chen, Mu-Hong [1 ,2 ,4 ]
Cheng, Chih-Ming [1 ,2 ,4 ]
Li, Cheng-Ta [1 ,2 ,4 ]
Tsai, Shih-Jen [1 ,2 ,4 ]
Lin, Wei-Chen [1 ,2 ,4 ]
Bai, Ya-Mei [1 ,2 ,4 ]
Su, Tung-Ping [1 ,2 ,3 ,4 ,5 ]
机构
[1] Taipei Vet Gen Hosp, Dept Psychiat, 201, Sec 2, Shih Pai Road, Taipei 112, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Fac Med, Div Psychiat, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan
[4] Natl Yang Ming Chiao Tung Univ, Inst Brain Sci, Taipei, Taiwan
[5] Cheng Hsin Gen Hosp, Dept Psychiat, Taipei, Taiwan
关键词
Treatment-resistant depression; Low-dose ketamine infusion; Repetitive transcranial magnetic stimulation; ANTIDEPRESSANT EFFICACY; INTRAVENOUS KETAMINE; SUICIDAL IDEATION; PREDICTORS;
D O I
10.1016/j.psychres.2022.114749
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: This posthoc analysis compared the antidepressant and antisuicidal effects of low-dose ketamine infusion with those of repetitive transcranial magnetic stimulation (rTMS) on treatment-resistant depression (TRD). Methods: In the ketamine infusion trial, 48 patients with TRD were randomized to receive a single infusion of 0.5 mg/kg ketamine or normal saline. In the rTMS trial, 105 patients were randomly assigned to intermittent thetaburst stimulation (iTBS), 10-Hz rTMS, or sham stimulation. The 17-item Hamilton Rating Scale for Depression (HDRS) was administered. Results: The antidepressant effect was prominent at Day 7 postinfusion in the ketamine group but steadily accumulated with the treatment duration from Day 7 to 14 in the iTBS and 10-Hz rTMS groups, regardless of the level of treatment resistance (all p < .01). Low-dose ketamine infusion and iTBS exerted superior effects on suicidal symptoms (HDRS item 3) than the other three groups (p < .001). The antidepressant effect of iTBS/10Hz rTMS may persist for up to 3 months; however, the antidepressant effect of a single low-dose ketamine infusion did not persist over a month. Discussion: Both low-dose ketamine infusion and rTMS/TBS must be included in TRD treatment but may be applied in different clinical situations.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial
    Paul E. Croarkin
    Ahmed Z. Elmaadawi
    Scott T. Aaronson
    G. Randolph Schrodt
    Richard C. Holbert
    Sarah Verdoliva
    Karen L. Heart
    Mark A. Demitrack
    Jeffrey R. Strawn
    Neuropsychopharmacology, 2021, 46 : 462 - 469
  • [32] Treatment of Alzheimer's Disease with Repetitive Transcranial Magnetic Stimulation Combined with Cognitive Training: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study
    Lee, Juyoun
    Choi, Byong Hee
    Oh, Eungseok
    Sohn, Eun Hee
    Lee, Ae Young
    JOURNAL OF CLINICAL NEUROLOGY, 2016, 12 (01): : 57 - 64
  • [33] High-Frequency Repetitive Transcranial Magnetic Stimulation Can Improve Depression in Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study
    Makkos, Attila
    Pal, Endre
    Aschermann, Zsuzsanna
    Janszky, Jozsef
    Balazs, Eva
    Takacs, Katalin
    Karadi, Kazmer
    Komoly, Samuel
    Kovacs, Norbert
    NEUROPSYCHOBIOLOGY, 2016, 73 (03) : 169 - 177
  • [34] Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study
    Mu-Hong Chen
    Chih-Ming Cheng
    Ralitza Gueorguieva
    Wei-Chen Lin
    Cheng-Ta Li
    Chen-Jee Hong
    Pei-Chi Tu
    Ya-Mei Bai
    Shih-Jen Tsai
    John H. Krystal
    Tung-Ping Su
    Neuropsychopharmacology, 2019, 44 : 2112 - 2118
  • [35] Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
    Maurizio Fava
    Marlene P. Freeman
    Martina Flynn
    Heidi Judge
    Bettina B. Hoeppner
    Cristina Cusin
    Dawn F. Ionescu
    Sanjay J. Mathew
    Lee C. Chang
    Dan V. Iosifescu
    James Murrough
    Charles Debattista
    Alan F. Schatzberg
    Madhukar H. Trivedi
    Manish K. Jha
    Gerard Sanacora
    Samuel T. Wilkinson
    George I. Papakostas
    Molecular Psychiatry, 2020, 25 : 1604 - 1604
  • [36] A randomized, controlled trial of sequential bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression
    Fitzgerald, PB
    Benitez, J
    de Castella, A
    Daskalakis, ZJ
    Brown, TL
    Kulkarni, J
    AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (01): : 88 - 94
  • [37] Neurocognitive aspects of ketamine and esketamine on subjects with treatment-resistant depression: A comparative, randomized and double-blind study
    Araujo-de-Freitas, Lucas
    Santos-Lima, Cassio
    Mendonca-Filho, Euclides
    Vieira, Flavia
    Franca, Ricardo J. A. F.
    Magnavita, Guilherme
    Cardoso, Tanise L.
    Correia-Melo, Fernanda S.
    Leal, Gustavo C.
    Jesus-Nunes, Ana Paula
    Souza-Marques, Breno
    Marback, Roberta
    Teles, Manuela
    Echegaray, Mariana V. F.
    Beanes, Graziele
    Guerreiro-Costa, Livia N. F.
    Mello, Rodrigo P.
    Rabanea, Thais
    Lucchese, Ana Cecilia
    Abreu, Neander
    Lacerda, Acioly L. T.
    Quarantini, Lucas C.
    PSYCHIATRY RESEARCH, 2021, 303
  • [38] Repetitive transcranial magnetic stimulation for functional tremor: A randomized, double-blind, controlled study
    Taib, Simon
    Ory-Magne, Fabienne
    Brefel-Courbon, Christine
    Moreau, Yse
    Thalamas, Claire
    Arbus, Christophe
    Simonetta-Moreau, Marion
    MOVEMENT DISORDERS, 2019, 34 (08) : 1210 - 1219
  • [39] Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial
    Bruun, Karin Due
    Amris, Kirstine
    Vaegter, Henrik Bjarke
    Blichfeldt-Eckhardt, Morten Rune
    Holsgaard-Larsen, Anders
    Christensen, Robin
    Toft, Palle
    TRIALS, 2021, 22 (01)
  • [40] Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial
    Karin Due Bruun
    Kirstine Amris
    Henrik Bjarke Vaegter
    Morten Rune Blichfeldt-Eckhardt
    Anders Holsgaard-Larsen
    Robin Christensen
    Palle Toft
    Trials, 22